Genetic Hyperglycemia Raises Risk of Coronary Artery Disease

Share this content:
Genetic Hyperglycemia Raises Risk of Coronary Artery Disease
Genetic Hyperglycemia Raises Risk of Coronary Artery Disease

MONDAY, March 27, 2017 (HealthDay News) -- Genetic predisposition to hyperglycemia raises the odds of coronary artery disease (CAD), independent of type 2 diabetes and other CAD risk factors, according to research published online March 15 in Diabetes Care.

Jordi Merino, Ph.D., from Massachusetts General Hospital in Boston, and colleagues conducted a discovery and validation genetic instrumental analysis to test the hypothesis that of all the potential metabolic contributors to type 2 diabetes and its metabolic consequences, genetically driven hyperglycemia alone has an effect on CAD risk. Analysis relied upon summary-level statistics from the largest published meta-analyses of genome-wide association studies for fasting glucose (FG; 133,010 participants free of diabetes) and CAD (63,746 case subjects and 130,681 control subjects).

The researchers found that using an instrumental variable analysis of 12 FG-raising variants, a 1 mmol/L increase in FG revealed an effect-size estimate of 1.43 CAD odds (95 percent confidence interval, 1.14 to 1.79). After excluding variants for heterogeneity and pleiotropic effects on other CAD risk factors, the association remained (odds ratio, 1.33; 95 percent confidence interval, 1.02 to 1.73). The 12 FG-increasing variants did not significantly increase type 2 diabetes risk (odds ratio, 1.05; 95 percent confidence interval, 0.91 to 1.23), and its prevalence was constant across FG genetic risk score quintiles (P = 0.72).

"These findings suggest that modulating glycemia may provide cardiovascular benefit," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »